UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

MYLAN LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Pennsylvania (State or other jurisdiction of Incorporation)		1-9114 (Commission File Number)		25-1211621 (I.R.S. Employer Identification No.)

(Address of principal executive offices)

(Registrant’s telephone number, including area code)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
	o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

 

 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

     (b) On January 31, 2007, Mylan Laboratories Inc., a Pennsylvania corporation (“Mylan”), announced that John P. O’Donnell, Ph.D., Mylan’s Chief Scientific Officer, will be retiring from the Company, effective as of April 1, 2007. Effective at such time, Dr. O’Donnell will serve as Mylan’s Strategic Scientific Advisor in the office of the CEO. A copy of the press release announcing Dr. O’Donnell’s retirement is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(c)

Exhibits.

99.1

Press Release of the Registrant dated January 31, 2007.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

99.1			Press Release of the Registrant dated January 31, 2007.